Medtronic plc (MDT) Revenue by Segment & Business Profile
Cardiovascular was 40.2% of Medtronic plc's revenue across the 5 lines it reports, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-07-31 · read by EquiReason
MDTMedtronic plcFollow MDT — free
—
Price chart with a free account
- Market cap
- 122.0B
- P/E TTM
- 23.4
- Dividend yield
- 3.0%
- 52-week
- —
- Next earnings
- 16 Nov, in 23 days
What the company does
Medtronic plc is a medical devices company in the healthcare sector. In its SEC filings it reports 5 business lines: Cardiovascular (40%), Neuroscience Group (28%), Medical Surgical (23%), Diabetes Group (9%) and others. Trailing twelve-month revenue: $37.5 billion as of 2026-07-31.
Roles we read
from the filings, not the sector label- Cardiovascular devices
- Neurology / nerve repair devices
Revenue by geography
latest quarter · company segment note| Region | Revenue | Share | y/y |
|---|---|---|---|
| United States | 4.91B | 50.3% | +16.2% |
| Total Other Countries Excluding United States and Ireland | 4.81B | 49.3% | +11.3% |
| Ireland | 40M | 0.4% | +21.2% |
Medtronic plc — questions
- What does Medtronic plc do?
- Medtronic plc is a medical devices company in the healthcare sector. In its SEC filings it reports 5 business lines: Cardiovascular (40%), Neuroscience Group (28%), Medical Surgical (23%), Diabetes Group (9%) and others. Trailing twelve-month revenue: $37.5 billion as of 2026-07-31.
- How does Medtronic plc make money?
- By the lines it reports in its SEC filings: Cardiovascular 40.2%, Neuroscience Group 27.5%, Medical Surgical 23.4%, Diabetes Group 8.6%, Other Operating Segment Misc 0.3% of revenue.
Every figure on this page comes from Medtronic plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.